← Leaderboards
Tianhong Li
Va Northern California Health Care Sys
$666,667
Attributed
$2,000,000
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2021–24$1M$750K$500K$250K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,000,000 · 1
VA$0 · 1
By mechanism
R44$2,000,000 · 1
I01$0 · 1
Others in their field
Other Emerging Leaders on “Malignant Neoplasm Of Lung”
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
- Greg Yothers · University Of Chicago$35,003,821
- Lynn Briscoe · Leidos Biomedical Research, Inc.$26,085,158
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$15,658,268
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- John Freymann · Leidos Biomedical Research, Inc.$14,011,208
Research focus
Malignant Neoplasm Of LungImmune Checkpoint InhibitorTumorNon-Small-Cell Lung CarcinomaBiopsyCellsImmunotherapySamplingCancer ImmunotherapyCancer PatientAffinityCessation Of LifeBiological MarkersAntibody TherapyCheckpoint TherapyClinical ApplicationCd8-Positive T-LymphocytesCancer EtiologyCancer CellCarcinomaCase StudyCell DeathBody FluidsBlood Specimen
Grant awards (6)
Targeting Integrins in Lung Cancer$0
I01 · FY2024 · VA · contact PI
Targeting Integrins in Lung Cancer$0
I01 · FY2023 · VA · contact PI
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy$1,000,000
R44 · FY2022 · CA
Targeting Integrins in Lung Cancer$0
I01 · FY2022 · VA · contact PI
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy$1,000,000
R44 · FY2021 · CA
Targeting Integrins in Lung Cancer$0
I01 · FY2021 · VA · contact PI